The common mutation of PIK3CA (encodes p110α, a 110 kDa catalytic subunit of Class IA) in cancer causes constitutive activation of PI3K and downstream Akt, and it is perhaps a promising target for therapy, but the mutation is not common in glioma despite 90% of GBMs harboring deregulated PI3K (116, 117). This evidence concerns the gene AKT1 and central nervous system cancer.